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Summary
Epidemiological studies of systemic amyloidosis are scarce and the burden
of disease in England has not previously been estimated. In 1999, the
National Health Service commissioned the National Amyloidosis Centre
(NAC) to provide a national clinical service for all patients with amyloido-
sis. Data for all individuals referred to the NAC is held on a comprehensive
central database, and these were compared with English death certiﬁcate
data for amyloidosis from 2000 to 2008, obtained from the Ofﬁce of
National Statistics. Amyloidosis was stated on death certiﬁcates of 2543
individuals, representing 058/1000 recorded deaths. During the same per-
iod, 1143 amyloidosis patients followed at the NAC died, 903 (79%) of
whom had amyloidosis recorded on their death certiﬁcates. The estimated
minimum incidence of systemic amyloidosis in the English population in
2008, based on new referrals to the NAC, was 04/100 000 population. The
incidence peaked at age 60–79 years. Systemic AL amyloidosis was the most
common type with an estimated minimum incidence of 03/100 000 popu-
lation. Although there are various limitations to this study, the available
data suggest the incidence of systemic amyloidosis in England exceeds 08/
100 000 of the population.
Keywords: amyloidosis, incidence, death certiﬁcate, survival.
Systemic amyloidosis is a disorder of protein folding in
which certain proteins auto-aggregate to form insoluble
amyloid ﬁbrils that accumulate in the extracellular space and
impair organ function. Amyloidosis is a progressive and usu-
ally fatal disease that has been loosely estimated to cause
about 05–10 deaths per thousand in the UK (Pepys, 2001),
mostly of systemic AL amyloidosis type. However, there are
almost no published epidemiological studies of amyloidosis
in the medical literature; the most comprehensive having
been a study conducted at the Mayo Clinic of the general
population residing in the surrounding area of Olmstead
County, USA (Kyle et al, 1992). They reported an incidence
of AL amyloidosis of 51–128 per million person-years, using
data from a centralized system recording virtually all medical,
surgical and pathological diagnoses of the county residents.
Twenty one individuals from Olmstead County were diag-
nosed with AL amyloidosis between 1952 and1992. The over-
all age- and sex-adjusted annual incidence rate was reported
to be 89 per million person-years. The authors extrapolated
that approximately 2225 new cases may occur annually
across the USA, but this has not been veriﬁed.
The UK National Amyloidosis Centre (NAC) provides a
diagnostic and treatment advisory service that is available
free of charge at the point of delivery to National Health Ser-
vice (NHS)-entitled patients with proven or suspected amy-
loidosis, and is the only specialist centre in the country. Data
on individuals referred to our centre are held on a compre-
hensive database that effectively serves as a national registry
of the disease. This database has enabled the natural history
and response to therapeutic interventions of the various
amyloidosis syndromes to be studied in large cohorts of
patients.
Studies using data from death certiﬁcates have been con-
ducted in several rare diseases to estimate the burden of
mortality (Cotch et al, 1996; Thomas et al, 2010; Marin et al,
2011) and indirectly estimate the incidence of disease. Sys-
temic amyloidosis lends itself to this approach because it is
an incurable and usually rapidly fatal disorder (Gillmore
et al, 2006, 2009; Lachmann et al, 2007; Kumar et al, 2010);
it has speciﬁc pathological features enabling deﬁnitive diag-
nosis through biopsy, and which are overt in hitherto undi-
agnosed cases at autopsy. Further, given the requirement for
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ing of amyloidosis on death certiﬁcates is exceptionally rare.
We estimate here the incidence of amyloidosis in England
based on an analysis of two data sets: reported death certiﬁca-
tion from the Ofﬁce of National Statistics (ONS) and infor-
mation on referrals and deaths held on the NAC database.
Methods
Ofﬁce of National Statistics (ONS) death certiﬁcate data
The number of deaths registered in each calendar year for
people living in England and the proportion of those deaths
in whom the word ‘amyloidosis’ appeared anywhere on the
death certiﬁcate, as deﬁned by the International Classiﬁcation
of Diseases ninth revision (ICD-9) code for the year 2000
and tenth revision (ICD-10) code from 2001 onwards
(Table I), were obtained from the ONS. All data was fully
anonymized.
Data from the National Amyloidosis Centre database
All English residents diagnosed to have systemic amyloidosis
between 2000 and 2008 whose details were held on the NAC
databases were identiﬁed and their details were provided to
ONS. Death data was returned from ONS for all matched
individuals, including date and cause of death as listed in
parts IA, IB, IC, and II of the respective death certiﬁcates.
Matching of individuals between the ONS and NAC databas-
es required agreement of name, date of birth and unique
NHS number. The type of amyloid and date of diagnosis was
obtained for each case from the NAC database and survival
from the ﬁrst assessment at NAC was calculated. Survival
data were censored on 1 January 2012.
Ofﬁce of National Statistics estimate of population
Estimates of the population in England were taken from the
ONS website ‘Mid-1971 to Mid-2010 Population Estimates:
Quinary age groups for Constituent Countries in the United
Kingdom; estimated resident population’ released on 21
December 2011 (available at: http://www.ons.gov.uk/ons/rel/p
op-estimate/population-estimates-for-uk–england-and-wales–
scotland-and-northern-ireland/population-estimates-timeserie
s-1971-to-current-year/index.html). Estimates are of the usu-
ally resident population on 30 June of the reference year and
reﬂectadministrative boundaries thatwere in place onthat day.
Ethics and statistics
The study was approved by the Royal Free Hospital ethics
committee. Graph Pad Prism version 5 (Graphpad software
Inc., San Diego, CA, USA) was used for statistical analyses.
Patient survival was estimated by Kaplan–Meier Analysis using
SPSS version 20 (IBM, New York, USA). The log-rank test was
used to compare differences between stratiﬁed Kaplan–Meier
survival curves. Statistical signiﬁcance was achieved if P <005.
Results
Accuracy of death certiﬁcate data
Summary statistics on the total number of deaths attribut-
able to systemic amyloidosis between 2000 and 2008 are
shown in Table II. Amyloidosis appeared on the death cer-
tiﬁcates of 2543 English individuals during this period.
There were 1143 deaths over the same period among
patients with systemic amyloidosis who were registered on
the NAC database, 903 (79%) of whom had amyloidosis
reported on their death certiﬁcate. The proportion of
patients registered on the NAC database for whom amyloi-
dosis was stated on the death certiﬁcate did not vary sig-
niﬁcantly over the study period. However, there was an
association between amyloid type and the frequency with
which amyloidosis appeared on the death certiﬁcate
(Table III, P  0001); 83% of patients with AL amyloi-
dosis had amyloidosis on their death certiﬁcate, compared
to 74% of those with hereditary amyloidosis and c. 62%
of those with AA and transthyretin amyloidosis.
Cause of death among patients with systemic amyloidosis
Among 903 patients who had amyloidosis on their death cer-
tiﬁcate and were followed for systemic amyloidosis at the
NAC, amyloidosis was recorded in part 1A, 1B, and 1C of
the death certiﬁcate in 261 (29%), 372 (41%) and 96 (10%)
cases respectively. Amyloidosis was recorded in part 2, which
identiﬁes conditions contributing to the cause of death, in
174 (19%) individuals (Fig 1). The primary cause of death
was probably directly related to amyloidosis among 127/174
(73%) such patients, and was listed as follows; 12 end-stage
renal failure (ESRF), 22 heart failure, 56 sepsis, 14 multi-
organ failure, 17 myeloma/lymphoma, ﬁve pulmonary embo-
lism and one nephrotic syndrome. A further 32 (18%) deaths
among these 174 individuals were possibly related to the
Table I. Amyloidosis deaths – International Classiﬁcation of Diseases
Ninth (ICD-9) and Tenth Revision (ICD-10).
Cause of death ICD-9 code
Amyloidosis 2773
Cause of death ICD-10 code
Non-neuropathic heredofamilial amyloidosis E850
Neuropathic heredofamilial amyloidosis E851
Heredofamilial amyloidosis, unspeciﬁed E852
Secondary systemic amyloidosis E853
Organ-limited amyloidosis E854
Other amyloidosis E858
Amyloidosis, unspeciﬁed E859
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cerebrovascular accidents (CVA), nine myocardial infarctions
(MI), four sudden cardiac deaths, one ruptured abdominal
aortic aneurysm and one bowel perforation. Only 15/174
(9%) deaths appeared unrelated to systemic amyloidosis, 14
from unrelated malignancies and one from chronic obstruc-
tive pulmonary disease (COPD).
Of the 240 individuals with systemic amyloidosis who
were followed at the NAC but did not have amyloidosis
stated on their death certiﬁcate, 179 (75%) had primary
causes of death which were probably related to their amyloid.
Among the remaining 61/240 (25%) patients the primary
cause of death was listed as follows; 26 ischaemic heart dis-
ease or heart failure, 13 ‘other’ malignancy, 10 CVA, 3
Table II. Total number of deaths in England with amyloidosis recorded anywhere on the death certiﬁcate and total number of patients from
England reviewed at the National Amyloidosis Centre (NAC) between 2000 and 2008.
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 Total
Data from death certiﬁcates (ONS)
Amyloidosis reported
as the underlying
cause of death (% of
total certiﬁcates
with amyloidosis stated)
128
(58)
154
(634)
171
(608)
153
(586)
165
(629)
197
(625)
174
(617)
208
(638)
217
(615)
1567
(616)
Amyloidosis anywhere on the
death certiﬁcate
220 243 281 261 262 315 282 326 353 2543
Total deaths in England 503 024 497 878 500 795 504 127 480 716 479 678 470 326 470 721 475 763 438 3028
Proportion of deaths
with amyloid mentioned
on death certiﬁcate
(per thousand deaths)
044 049 056 050 54 066 060 069 074 058
Data from NAC database
Deaths in patients seen at NAC, N 66 84 98 110 116 144 151 157 217 1143
NAC deaths with amyloid on
certiﬁcate, N (%)
55
(833)
69
(821)
82
(837)
87
(791)
87
(75)
119
(826)
118
(781)
116
(739)
170
(783)
903
(790)
Total deaths with amyloid on
death certiﬁcate and conﬁrmed
NAC deaths with
no mention of amyloid, N
231 258 297 284 291 340 315 367 400 2783
National proportion of deaths
with amyloid from death certiﬁcate
and NAC conﬁrmed cases
(per thousand deaths)
046 052 059 056 061 071 067 078 084 063
Patients with amyloid on
death certiﬁcate
not seen at NAC, N (%)
165
(75)
174
(716)
199
(708)
174
(666)
175
(668)
196
(622)
164
(582)
210
(644)
183
(518)
1640
(645)
ONS, Ofﬁce of National Statistics; NAC, National Amyloidosis Centre.
Table III. Number of patients seen at the National Amyloidosis Centre with amyloid on their death certiﬁcate, stratiﬁed by amyloid ﬁbril type.
Amyloid mentioned on death certiﬁcate
AL amyloidosis AA amyloidosis
Hereditary
amyloidosis
Senile systemic
amyloidosis
No Yes No Yes No Yes No Yes
2000 4 (8) 46 (92) 6 (60) 4 (40) 1 (167) 5 (833) 0 0
2001 7 (103) 61 (897) 5 (385) 8 (615) 3 (100) 0 0 0
2002 12 (153) 72 (847) 3 (429) 4 (571) 1 (143) 6 (857) 0 0
2003 16 (184) 71 (816) 5 (294) 12 (706) 0 4 (100) 2 (100) 0
2004 16 (182) 72 (818) 6 (546) 5 (454) 2 (223) 7 (777) 5 (625) 3 (385)
2005 22 (181) 100 (819) 2 (143) 12 (857) 1 (125) 7 (875) 0 0
2006 23 (193) 96 (807) 6 (316) 13 (684) 4 (40) 6 (60) 0 3 (100)
2007 27 (223) 94 (777) 11 (478) 12 (522) 1 (167) 5 (833) 2 (286) 5 (714)
2008 33 (9) 139 (81) 6 (375) 10 (625) 6 (30) 14 (70) 2 (223) 7 (777)
Total (%) 160 (175) 751(824) 50 (385) 80 (615) 19 (26) 54 (74) 11 (379) 18 (621)
Epidemiology of Systemic Amyloidosis
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stage renal failure, bowel obstruction, bowel ischaemia, pelvic
abscess, peritonitis, and vasculitis. Taken together, these
results suggest that amyloidosis contributed directly to death
in more than 90% of patients with systemic amyloidosis.
Estimate of deaths attributable to amyloidosis in
England
According to death certiﬁcate data, 058 per thousand deaths
were attributable to amyloidosis in England between 2000
and 2008. Over the 9-year period, there was a signiﬁcant
increase in the proportion of death certiﬁcates on which
amyloidosis was included as a cause of death (Fig 2, R
2 086,
P  0001). Given that 21% of patients who were known to
the NAC with systemic amyloidosis did not have ‘amyloido-
sis’ mentioned on their death certiﬁcates, we estimated that
at least the same proportion of cases may not be reported on
death certiﬁcates in England generally. Assuming 21% deaths
from systemic amyloidosis were not reported on English
death certiﬁcates between 2000 and 2008, the total number
of individuals who died from systemic amyloidosis in Eng-
land during this time period was 3077 [2543 (79%
reported) + 534 (21% unreported)], representing 07 per
1000 deaths in the country. Taking only the data for 2008
and using the same calculation (i.e., assuming 21% deaths
from systemic amyloidosis were not reported as such), the
total number of deaths from systemic amyloidosis in England
in 2008 was 429, representing 09 per 1000 (429/475 763)
deaths.
Estimate of incidence and prevalence of amyloidosis in
England
Referrals to the NAC of patients with systemic amyloidosis
(Table IV) doubled over the 9 year study period (R
2 08167,
P = 00008) from 02 per 100 000 population in 2001 to 04
per 100 000 population in 2008. The incidence increased
with age and peaked between 60 and 79 years. A proportion
of patients with systemic amyloidosis are not referred to the
NAC, and although this proportion appeared to fall substan-
tially between 2000 and 2008 (Table II), it is only possible to
reliably estimate the minimum disease incidence from NAC
data. The twofold increase in referrals to the NAC between
2000 and 2008 is likely to reﬂect a combination of increased
awareness of the disease and demand for NAC services, as
well as improvement in diagnosis. In 2008, 482% of the
individuals in England in whom amyloidosis was recorded
on their death certiﬁcate had been assessed at the NAC.
Extrapolation to the population of England generally suggests
an annual incidence in 2008 of 08/100 000 persons. Table V
shows the number of patients in England diagnosed with dif-
ferent types of systemic amyloidosis at the NAC. Systemic
AL amyloidosis is the most prevalent, with a minimum over-
all incidence of 03 cases per 100 000 population in 2008,
which increases to 05 per 100 000 when the estimated
518% of patients who were not seen at the NAC are
included.
According to NAC data, there were 435 individuals living
in England with systemic amyloidosis in 2000 and 1051 indi-
viduals living with the disease in 2008. This apparent increase
in prevalence is likely, in part, to reﬂect improved survival
[median (95% conﬁdence interval) 276 (164–389) months
in 2000 vs. 45 (432–467) months in 2008; log rank test for
trend P = 002; Table VI], as well as changing referral
patterns.
Regional differences in death rates and referrals to the
NAC
The regional differences across England in reported deaths
from amyloidosis in 2008 are shown in Table VII. The pro-
portion of deaths ranged from a minimum of 055/1000 in
Yorkshire and the Humber to a maximum of 097/1000 in
the South West. There were signiﬁcantly less deaths reported
in Yorkshire and the Humber compared to the East of Eng-
land, South Central and the South West (P < 001). There
was no correlation between the proportion of deaths from
amyloidosis and distance from the NAC. The number of new
referrals to the NAC did vary between strategic health
authorities (SHAs) however, with a greater number of
patients being referred from SHAs located closer to the NAC
Fig 1. Position of amyloidosis on death certiﬁcates among patients
who attended the National Amyloidosis Centre.
Fig 2. Proportion of death certiﬁcates from England on which
amyloidosis was included as a cause of death.
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British Journal of Haematology, 2013, 161, 525–532(Fig 3). It would appear that nearly all patients who died
from systemic amyloidosis in London and the East of
England regions had been seen at the NAC. These regions
are therefore likely to offer the greatest accuracy for estimat-
ing disease incidence. The minimum estimated disease inci-
dence in these two regions respectively, based on new patient
referrals to the NAC, was 073 and 056/100 000 population,
corroborating earlier calculations of disease incidence.
Discussion
Information regarding the epidemiology of systemic amyloi-
dosis is scarce. The most robust study (Kyle et al, 1992)
reported the incidence to be 89 per million person years.
This study used patient record data from Olmstead County,
USA to identify patients diagnosed with the disease between
1950 and 1989, and incidence was extrapolated on the basis
of population data for the whole of the USA. The authors
noted an increase in incidence across the time period (Kyle
et al, 1992). The ﬁndings from the Olmstead County study
have not been validated or updated; furthermore, the
epidemiology of systemic amyloidosis has not previously
been studied in England. A report from Boston University
used death certiﬁcate data to estimate the number of deaths
from systemic AL amyloidosis. Although the diagnostic crite-
ria for AL amyloidosis were somewhat unreliable in this
study, the estimated incidence based on mortality data was
45/100 000 (Simms et al, 1994). Imaizumi (1989) used
death certiﬁcates to estimate the rate of death from systemic
amyloidosis in Japan, expressed as the number of cases with
amyloid on death certiﬁcates per 100 000 population alive
during that year. They reported an increase in death rate
from amyloid among males from 0022/100 000 in 1969 to
0178/100 000 in 1992 (Imaizumi, 1989).
Death certiﬁcates have previously been used to estimate
incidence in a number of rare diseases (Marin et al, 2011).
Death certiﬁcate data is deemed a reliable way of estimating
disease incidence only in conditions which are well deﬁned,
rarely misdiagnosed, and consistently fatal without changing
survival (Marin et al, 2011). The sensitivity of mortality data
for predicting disease incidence in systemic AL amyloidosis
has not been systematically determined; on the one hand,
there are well deﬁned diagnostic criteria, it has a high mor-
tality and short survival (Simms et al, 1994), on the other
hand, it may be misdiagnosed (Lachmann et al, 2002) and
survival has steadily been improving probably as a result of
increased use of novel drug therapies (Kumar et al, 2010;
Kastritis et al, 2012; Venner et al, 2012), introducing uncer-
tainty into calculations of disease incidence. In this study, we
determined that amyloidosis was present on the death certiﬁ-
cates of 79% of individuals with known systemic amyloidosis
in England and 825% of individuals with known systemic
AL amyloidosis. Using the information from death certiﬁ-
cates, an estimated 058/1000 deaths in England were attrib-
utable to amyloidosis, with a signiﬁcant increase reported
over the decade. Among those reviewed at the NAC who
died, 80% had AL amyloidosis. One would estimate therefore
that c. 046/1000 deaths in England are attributable to AL
amyloidosis. Patient survival increased substantially between
2000 and 2008; one would therefore be reluctant to estimate
disease incidence from death certiﬁcate data alone.
Table V. Estimated age-adjusted annual incidence in 2008 of each amyloid type per hundred thousand population in England assuming that all
patients with amyloidosis are seen at the National Amyloidosis Centre.
Age range
(years)
Number of patients (annual incidence per hundred thousand patients)
AL amyloidosis AA amyloidosis Senile systemic amyloidosis Hereditary amyloidosis and other
0–19 0 3 (003) 0 0
20–29 0 3 (004) 0 0
30–39 1 (001) 6 (008) 0 3 (004)
40–49 11 (01) 5 (006) 0 1 (001)
50–59 38 (06) 7 (01) 0 5 (008)
60–69 59 (10) 14 (02) 1 (002) 8 (01)
70–79 54 (10) 9 (02) 10 (03) 9 (02)
80+ 11 (05) 1 (005) 7 (03) 0
Total 174 (03) 48 (008) 18 (003) 26 (004)
Table VI. Kaplan–Meier survival from the date of diagnosis among
patients diagnosed with amyloidosis at the National Amyloidosis
Centre by individual year of diagnosis.
Year of diagnosis
Median survival (months)
Estimate 95% Conﬁdence interval
2000 2771 6 4–389
2001 3321 6 7–497
2002 1741 1 3–235
2003 3232 0 5–441
2004 2751 6 2–388
2005 2921 8 5–398
2006 3602 0 5–516
2007 3392 3 1–447
2008 4504 3 2–467
Overall 3182 7 4–362
Log rank (Mantel Cox) for trend P = 0023.
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British Journal of Haematology, 2013, 161, 525–532Individual level data for patients reviewed at the NAC are
likely to be extremely reliable, particularly with respect to
presence and type of amyloid. Only 482% of patients with
systemic amyloidosis who died in 2008 had been seen at the
NAC however, clearly suggesting that not all patients with
systemic amyloidosis in England are seen at the centre. An
estimate of incidence of systemic amyloidosis that is calcu-
lated solely on the basis of NAC cases would undoubtedly be
an underestimate; however, 04 per 100 000 population in
2008 can reliably be considered a minimum disease inci-
dence. The true incidence of systemic amyloidosis is likely to
be approximately double this Figure, c. 08 per 100 000,
although once again, this may be an underestimate given that
21% of patients with systemic amyloidosis do not have amy-
loidosis on their death certiﬁcates. Without a national regis-
ter of all cases of amyloid however, these limitations cannot
be addressed.
The incidence, and/or the recognition of systemic amyloi-
dosis appear to be increasing. Data from Olmstead County
showed an apparent rise in incidence of AL amyloidosis dur-
ing the last decade of their analyses. In the present study,
there was a signiﬁcant rise each year in the number of indi-
viduals with amyloidosis on their death certiﬁcate, accompa-
nied by a parallel rise in the number of patients with
systemic amyloidosis assessed at the NAC throughout the
study period. This apparent rise may reﬂect an actual
increase in disease incidence but could equally well be attrib-
uted to better awareness of the disease itself and/or existence
of a national referral centre as well as improved diagnostic
techniques.
Study limitations
From a combination of NAC data and death certiﬁcate data
we have been able to robustly calculate the sensitivity of
death certiﬁcates in reporting systemic amyloidosis. Unfortu-
nately, we were unable to calculate the speciﬁcity of death
certiﬁcate data for reporting systemic amyloidosis because we
do not have further clinical information on many of the rele-
vant individuals although, given that amyloid histology is
required for diagnosis and is extremely speciﬁc, one can
assume that speciﬁcity is likely to be very high. We have used
Table VII. Total deaths and National Amyloidosis Centre deaths from amyloidosis and incidence based on new referrals to the NAC in 2008 by
Strategic Health Authority.
Strategic
Health
Authority
ONS
total
deaths
ONS
population
estimates
Amyloidosis
on death
certiﬁcate
Proportion of
deaths due to
amyloidosis (per
thousand)
Deaths from
amyloidosis
(per 100 000
population)
New patients
diagnosed with
amyloid at NAC
Incidence of
amyloidosis (based on
newly diagnosed NAC
cases) per 100 000
Number
of deaths
in NAC
patients
North East 27 386 2 570 600 20 073 077 2 007 4
North West 70 740 6 874 100 45 063 065 24 035 24
Yorkshire and
the Humber
50 539 5 217 500 28 055 054 22 042 13
East Midlands 42 296 4 429 400 25 059 056 21 047 8
West Midlands 52 318 5 408 400 33 063 061 35 064 13
East of England 52 689 5 717 400 49 093 085 32 056 50
London 50 476 7 668 300 42 083 054 56 073 38
South East Coast 42 537 4 309 400 26 061 062 4 0 55 16
South Central 33 380 4 059 100 33 098 081 26 064 24
South West 53 402 5 210 400 52 097 099 25 047 27
Total 475 763 51 464 600 353 074 068 267 052 217
ONS, Ofﬁce of National Statistics; NAC, National Amyloidosis Centre.
Fig 3. Apparent incidence of amyloidosis in
2008 stratiﬁed by Strategic Health Authority,
derived solely from new referrals to the
National Amyloidosis Centre (NAC). The inci-
dence appears to fall as distance from the NAC
increases (R
2 = 064, P = 0005).
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British Journal of Haematology, 2013, 161, 525–532the number of deaths among amyloidosis patients who were
not seen at our centre to make an estimate of the total num-
ber of patients with amyloidosis in England; however, we do
not know the proportion of patients who are diagnosed with
amyloidosis but never seen at the NAC that have amyloidosis
on their death certiﬁcates. It is conceivable that patients with
systemic amyloidosis who do attend the NAC are more likely
to have amyloidosis on their death certiﬁcate than those with
systemic amyloidosis who do not attend the NAC.
Conclusion
Death certiﬁcates are a reasonably sensitive method for
detecting the proportion of deaths attributable to systemic
amyloidosis in England. The proportion of individuals diag-
nosed with systemic amyloidosis who are seen at the UK
NAC is increasing each year. We estimate that the annual
incidence of systemic amyloidosis in 2008 was approximately
08 per 100 000 population.
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